CJC-1295

most data

Also seen as: With DAC / No DAC, CJC, Mod GRF 1-29, modified GRF, CJC-1295 with DAC, CJC-1295 No DAC, Modified GRF 1-29

The Dose Guy’s verdict

Aug 28, 2026
2 sources

If you want your own GH axis working harder without injecting growth hormone directly, CJC-1295 is the GHRH side of the best pairing available. Stack it with ipamorelin, run it consistently, and it does what it should: a clean, sustained push on your pituitary to release more of your own GH. The human data is thin, no body-composition trial exists, but the mechanism is nailed down and the community has years on it.

Would I take it?Yes, the backbone.

What it is

CJC-1295 is a growth hormone-releasing hormone analog, a modified version of the signal your hypothalamus already sends to your pituitary to release GH. Two forms exist and the distinction matters. The original published molecule carries a drug affinity complex that hooks onto serum albumin and stretches the active window to days, which sounds like a win but means one long, blurry GH elevation instead of the sharp pulses your body runs natively. So the community landed on the no-DAC form, sold as Mod GRF 1-29, which carries four amino acid swaps for enzymatic stability but clears fast enough to fire clean pulses. CJC-1295 is itself a secretagogue, on the GHRH side. Pair it with ipamorelin on the GHRP side: one primes the pituitary, the other pulls the trigger, and together they produce a bigger, cleaner pulse than either alone.

This pairing is the standard entry point for the GH axis. If it is not enough, HGH is what you graduate to.

What the research shows

The mechanism is well-characterized. The outcome data barely exists, and all of it is on the DAC molecule, not the no-DAC form the community actually runs. What the published studies hold is healthy-adult endocrine data on the albumin-bound version:

One subcutaneous injection increased mean plasma GH two- to tenfold for at least 6 days and raised IGF-I 1.5- to threefold for 9 to 11 days.JCEM 2006 · RCT · healthy adults

One week after a single dose, basal trough GH was 7.5-fold higher and IGF-I was up 45%, with GH pulsatility fully preserved.JCEM 2006 · healthy men

No controlled human trial measuring muscle gain, fat loss, performance, or injury healing exists for either form. The no-DAC version most people run has never been in a human study at all. The physique case is mechanism plus firsthand logs.as of Aug 2026

Realistic protocols

The no-DAC form is what you run. Pin it subcutaneously, on an empty stomach, because food blunts the GH pulse. Pre-bed is the anchor shot, riding your natural overnight GH surge. Most people stack it with ipamorelin in the same syringe, drawn together after reconstituting each vial separately with bacteriostatic water. The empty-stomach requirement means keeping a window between your last meal and the shot, usually two hours or more. If the pre-bed pin shifts your dinner earlier, that is the compound changing your routine, and it is the main practical adjustment. The receptor saturates at a modest dose, so piling on more does not buy proportionally more GH. Consistency matters more than milking every shot.

If you run the DAC version instead, the dosing flips: one or two pins a week at a higher total dose, because the albumin binding keeps it active for days. The tradeoff is that you lose the clean pulse pattern, and most people who try both settle on no-DAC for that reason.

No-DAC dose100 mcgSub-q, empty stomach. The saturating dose for most people.

Frequency1–3x dailyPre-bed at minimum. Add a morning or pre-workout shot on the full stack.

The stack+ ipamorelinSame syringe, same timing. GHRH primes, GHRP fires.

DAC alternative1–2 mg/wkOne or two pins a week. Sustained elevation, blurrier pulse. Most people prefer no-DAC.